Medicine
Rybelsus 3 mg tablet
Rybelsus 3 mg tablet is a prescription medicine containing Semaglutide for oral use, marketed by Novo Nordisk Pharmaceutical Industries, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store RYBELSUS and OZEMPIC tablets at 20°C to 25°C (68°F to 77°F), excursions…
Key facts
- Active ingredient (INN)
- Semaglutide
- Brand
- Rybelsus
- Strength
- 3 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets
- Marketing authorisation holder
- Novo Nordisk Pharmaceutical Industries
- Manufacturer
- Novo Nordisk Pharmaceutical Industries
- Origin register
- US FDA, United States
- Storage
- Store RYBELSUS and OZEMPIC tablets at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store and dispense in the original bottle. Store tablets in the original bottle until use to protect tablets from moisture. Store product in a dry place away from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10BJ06 Semaglutide
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 September 2019
- Identifiers
- RxCUI 2200644, 2200650, 2200652 +7DailyMed set ID 27f15fac-7d98-4114-a2ec-92494a91da98NDC 0169-4303Application NDA213051
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet in 1 bottle, plastic | 0169-4303-30 | Novo Nordisk Pharmaceutical Industries | 4 October 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Semaglutide
Clinical summary
Semaglutide is a GLP-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, among other approved uses. MedsAcross supplies Semaglutide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SemaglutideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- OZEMPIC prescribing information (Novo Nordisk Pharmaceutical Industries) · U.S. National Library of Medicine, DailyMed
- Kayshild: European public assessment report (EPAR) · European Medicines Agency
- Ozempic: European public assessment report (EPAR) · European Medicines Agency
Need Rybelsus 3 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.